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Gregory L. Moneta, MD, Abstracts Section EditorFactors affecting symptomatic vs asymptomatic vein graft stenoses in
lower extremity bypass grafts
Landry GJ, Liem TK, Mitchell EL, et al. Arch Surg 2007;142:848-54.
Conclusions: Symptomatic vein graft stenosis is associated with the
presence of distal vein graft lesions, alternative conduit grafts, and larger
decreases in the ankle-brachial index (ABI). Graft patency after graft revision
is not affected by whether the vein graft stenosis was or was not associated
with symptoms.
Summary: Stenosis of lower extremity vein grafts is often asymptom-
atic. This study was undertaken to characterize symptomatic vs asymptom-
atic vein grafts and to determine if the presence of symptoms influenced
subsequent patency of vein grafts after revision. This was a retrospective
analysis of a prospectively maintained database from a combined University
and Department of Veterans Affairs Vascular Surgical Service. There were
219 lower extremity vein graft revisions performed in 161 patients between
January 1995 and January 2007. Patients with vein graft stenoses were
considered symptomatic if they had recurrence of the symptoms that had
prompted the original placement of the vein graft. Both univariate and
multivariate analysis were used to develop amodel of independent predictors
of symptomatic recurrence. Patency rates for symptomatic and asymptom-
atic stenotic vein grafts were compared after revision.
There were 125 asymptomatic and 94 symptomatic vein graft lesions
revised. Lesions associated with symptoms had a significantly greater drop in
ABI than asymptomatic lesions (0.21  0.03 vs 0.18  0.02, P  .003).
Vein graft stenoses that were located in the distal graft or in the outflow
artery were also more likely to be associated with symptom recurrence (P 
.048). By multivariate analysis, a decrease in ABI (odds ratio, 6.803; 95%
confidence interval [CI], 1.418-32.258; P .02) and use of alternative vein
conduits (odds ratio. 2.633; 95% CI, 1.243-5.578; P  .01) were indepen-
dent predictors of symptomatic vein graft stenosis. There were also strong
trends towards symptomatic recurrence being associated with other systemic
manifestations of atherosclerosis such as cerebrovascular disease or coronary
artery disease (P  .06). Patients with diabetes or renal failure and current
smokers were not more likely to present with recurrent symptoms. Symp-
tomatic stenoses were more frequent in revisions performed between 1 and
2 years postoperatively (56%) than in the first year after the operation (37%,
P .003). Assisted primary patency rates of grafts revised with symptomatic
vs asymptomatic stenoses were not different (82% symptomatic and 88%
asymptomatic at 5 years; P  .30).
Comment:The article defines, for the first time, factors associated with
symptomatic vein graft stenoses. Unfortunately, although stenoses revised in
alternative conduit grafts and stenoses revised 1 year after graft implanta-
tion are more frequently associated with symptoms, a significant number of
patients in those groups also have asymptomatic graft stenosis of sufficient
severity that the graft requires revision. At this time, a life-long policy of
periodic surveillance of lower extremity vein grafts with duplex scanning still
seems prudent.
Shifting paradigms in the treatment of lower extremity vascular dis-
ease: A report of 1000 percutaneous interventions
DeRubertis BG, Faries PL, McKinsey JF, et al. Ann Surg 2007;246:415-
424.
Conclusion: The first-line therapy for patients with chronic lower
extremity ischemia should be a percutaneous intervention.
Summary: The authors report retrospective analysis of 1000 percuta-
neous infrainguinal interventions. Claudication was the indication for inter-
vention in 46.3%, and limb-threatening ischemia was the indication in 52.7%
(rest pain, 27.7%; tissue loss, 72.3%). Patients were treated with a variety of
catheter-based techniques, including angioplasty, angioplasty and stenting,
laser angioplasty, and atherectomy. Femoral, popliteal, and tibial vessels
were treated. Men comprised 57.3% of patients, 58% of patients had diabe-
tes, and chronic renal insufficiency was present in 39%. The 30-day mortality
rate was 0.5%. In patients with claudication, 2-year primary and secondary
patency rates were 62.4% and 79.3%. At 2 years, only 0.5% of claudicant
patients had undergone amputations. In patients with limb-threatening
ischemia, rates for 2-year primary patency, secondary patency, and limb
salvage were 37.4%, 55.4%, and 79.3%, respectively. Predictors of recurrent
disease included limb threat as the indication for intervention (P  .0001),
hypercholesterolemia (P  .001), diabetes (P  .003), coronary artery
disease (P  .047), and TransAtlantic Inter-Society Consensus (TASC) D
lesions (P .050). Of the patients with recurrent disease, 60.3% underwent
a successful percutaneous reintervention, 7.5% required no further interven-
tion, 11.7% underwent bypass, and 20.5% had amputation.
478Comment: This is a retrospective analysis of a large number of patients
treated for evolving indications with continually changing technology. The
results are not surprising, and the predictors of failure not unexpected.
Unfortunately, this lesion-based analysis is out dated. The authors also did
not tell us about those who were medically managed, those treated with
open operations, the nature of the wounds in the patients with critical limb
ischemia, and who underwent primary amputation. There was no quality of
life evaluation in those treated. Compared with most open series of infrain-
guinal revascularization, a high percentage of the patients had claudication.
Overall, the article tells us what a group of surgeons with seemingly relatively
liberal indications for intervention and favoring catheter-based techniques
did. It also tells us a bit about how the intervention worked out. It doesn’t
really tell patients how it will work out for them, nor does it tell surgeons
what they should do.
Effect of statin withdrawal on frequency of cardiac events after vascular
surgery
Schouten O, Hoeks SE, Welten GM, et al. Am J Cardiol 2007;1000:
316-20.
Conclusion: Statin withdrawal in the perioperative period after vascu-
lar surgery is associated with increase risks of perioperative adverse cardiac
events.
Summary: The incidence of adverse cardiac events increases in patients
with acute coronary syndrome who have withdrawal of their statin medica-
tion (J Cardiothorac Anesthes 2003;17:90-100). There are no intravenous
formulas for statins, thus interruption of statins in the postoperative period
occurs frequently, especially in patients with postoperative ileus. In this
study, the authors studied 298 consecutive patients who underwent major
vascular surgery and who were also taking a statin medication. The goal of
the study was to assess the effect of postoperative cardiac outcome after
perioperative statin withdrawal.
Patients were evaluated with detailed cardiac history and determination
of medication use, including the particular type of statin each patient was
taking. Troponin levels were measured on postoperative days 1, 3, and 7,
and 30. Troponin levels were also obtained whenever indicated clinically by
electrocardiographic changes. End points of the study were myocardial
infarction, postoperative troponin release, and a combination of cardiovas-
cular death and nonfatal myocardial infarction. Cox proportional hazard
analysis and multivariant analysis were used to assess the influence of statin
type and the effect of discontinuation of statins on occurrence of study end
points.
Perioperative discontinuation of statin medication was associated with
an increased risk of troponin release (hazard ratio [HR], 4.6; 95% confidence
interval [CI], 2.2-9.6). Statin discontinuation was also associated with an
increased risk of the combination of cardiovascular death and myocardial
infarction (HR, 7.5; 95% CI, 2.8-10.1). Fluvastatin, an extended-release
statin, was associated with fewer perioperative events compared with prava-
statin, simvastatin, and atorvastatin.
Comment: Evidence is accumulating that statin withdrawal in the
perioperative period is harmful for vascular surgical patients. Obviously, this
is not due to perioperative changes in lipid levels but likely involves some of
the pleiotropic effects of statins, such as inhibition of inflammation, anti-
thrombotic effects, and modulation of endothelial function. Pleiotropic
effects are present within hours of statin administration. Such effects can be
rapidly lost with acute withdrawal of a statin medication. Whenever possible,
vascular surgical patients should be started on statins preoperatively and
maintained on statins during their perioperative period.
TGF-Beta and CTGF-Mediated Fibroblast Recruitment Influences
Early Outward Vein Graft Remodeling
Jiang Z, Yu P, Tao M, et al. Am J Physiol Heart Circulatory Physiol 2007;
293: H482-H488.
Conclusions: Elevated wall shear stress increases production of tissue
growth factor- (TGF-) and connective tissue growth factor (CTGF) leading
to increased differentiation of fibroblasts to myofibroblasts. Levels of TGF-
and CTGF correlate inversely with outward remodeling of the vein graft wall.
Summary: Placement of a venous conduit into an arterial system leads
to acute alterations in shear stress in the vein graft wall. Shear influences both
the morphology of the graft wall and intramural growth. Increased wall
shear promotes luminal expansion, and elevated circumferential wall stress
leads to wall thickening and stabilization of luminal diameter. Both TGF-
and CTGF regulate adventitial remodeling. The authors postulate increased
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provoke adventitial reorganization to limit outward remodeling of the vein
graft in response to increased intramural wall stress.
The authors created a model using a distal arterial venous fistula in the
neck of rabbits that results in circumferential wall shear stress. Neck and
fistula veins were harvested at 1, 3, and 7 days after implantation. Flow rates
were recorded at the time of graft implantation and harvest using an
ultrasonic flow meter. Real-time polymerase chain reaction and enzyme-
linked immunosorbent assays were used to assess production of CTGF and
TGF-1.
With this model, the authors demonstrated increased production of
TGF- and CTGF in response to elevated wall stress. TGF- and CTGF
increased expression correlated with enhanced differentiation from fibro-
blasts to myofibroblasts, as reflected in increases in the -actin–positive cells
in the adventitia. Levels of -actin, TGF-, and CTGF were all inversely
correlated with outward remodeling of the graft wall.
Comment: Wolinsky and Glagov originally demonstrated arterial
adaption to maintain lumen diameter in atherosclerotic arteries. In vein
grafts, this adaptive response might be limited by TGF- and CTGF
increases in myofibroblasts. Such an adaption may maintain vein wall
integrity in the face of increased intraluminal pressure but may ultimately
prove disadvantageous because it may limit the ability of the vein graft to
maintain luminal diameter in response to the development of intimal
hyperplasia.
Temporary worsening of renal function after aortic surgery is associ-
ated with higher long-term mortality
Welten GM, Schouten O, Chonchol M, et al. Am J Kidney Dis 2007;50:
219-28.
Conclusion: Temporary worsening of renal function after open sur-
gery for abdominal aortic aneurysm (AAA) is associated with an increased
long-term mortality rate.
Summary: The authors sought to determine the effects of temporary
renal dysfunction on the long-term mortality rate in patients undergoing
AAA surgery. From January 1995 to June 2006, 1324 patients underwent
elective open AAA repair in a single center in Rotterdam. Creatinine clear-
ance was measured preoperatively and on postoperative days 1, 2, and 3. The
patients were then divided into three groups. Group 1 had improved or
unchanged renal function. Group 2 had temporary worsening of renal
function with a 10% decrease on day 1 or 2, and then recovery 10% of
baseline by day 3. Group 3 patients had persistent worsening of renal
function as defined by a 10% decrease in creatinine clearance compared
with the baseline value.
The 30-day mortality rates in groups 1, 2, and 3 were 1.2%, 5%, and
12.6%, respectively. Adjusting for postoperative complications and baseline
characteristics, the 30-day mortality rate was greatest in the patients with
persistent worsening of renal function (hazard ratio (HR), 7.3; 95% confi-
dence interval [CI], 2.7-19.8). Those who had temporary worsening of
renal function also had an increased mortality risk (HR, 3.7; 95% CI,
1.4-9.9). Follow-up was for 6.0 3.4 years. During follow-up, 348 patients
(36.5%) died. The HR for late death was 1.7 (95% CI, 1.3-2.3) in the
patients who had persistent worsening of renal function. For those who had
temporary worsening of renal function, the HR for death was 1.5 (95% CI,
1.2-1.4). There was a significant association between perioperative blood
loss and worsening of renal function (P  .001) and between length of
suprarenal aortic clamping and worsening of renal function (P  .001).
There was also a greater incidence of hypertension in the patients with
temporary and persisting renal dysfunction (P  .001).
Comment: Another recent study suggested minimal changes in renal
function after cardiothoracic surgery had little impact on long-term prog-
nosis (J Am Soc Nephrol 2004;15:1597-605). The current study reaches an
opposite conclusion. Although this study was retrospective, the mean follow-
up was long (6 years) and the number of patients was large (n 1324). It is
reasonable, therefore, to conclude that any significant worsening of periop-
erative renal function in an AAA patient carries an adverse prognosis both in
the near- and long-term. Although it seems nice when transient renal
dysfunction after AAA surgery returns to baseline levels, it doesn’t appear to
do the patient any good.
Effects of random allocation to vitamin E supplementation on the
occurrence of venous thromboembolism: Report from the Women’s
Health Study
Glynn RJ, Ridker PM, Goldhaber SZ, et al. Circulation 2007;116:1497-
503.
Conclusion: Vitamin E supplementation lowers the risk of venous
thromboembolism (VTE).
Summary: Vitamin E supplementation may serve as a natural antago-
nist of vitamin K in healthy adults. Whether vitamin E can sufficiently
antagonize vitamin K activity to decrease the risk of VTE is unknown. The
Women’s Health Study tested the effects of vitamin E supplementation for10 years on the risk of cardiovascular disease or cancer in a large group of
women without these diseases at study entry. The study randomized 39,876
women aged 45 years to receive 600 IU of vitamin E, or placebo, on
alternate days. Before randomization, blood samples were obtained from
26,779 participants to determine G20210A prothrombin gene mutation,
factor V Leiden, and 5,10 methylenetetrahydrofolate reductase (MTHFR)
gene polymorphisms. The authors evaluated development of unprovoked
VTE (no known diagnosis of cancer and no recent surgery or trauma).
During a median follow-up of 10.2 years, VTE developed in 482
women, 213 in the vitamin E group and 269 in the placebo group, a 21%
hazard reduction in the vitamin E group (relative hazard, 0.79; 95% confi-
dence interval [CI], 0.66-0.94; P .010). For unprovoked VTE, the hazard
reduction was 27% (relative hazard, 0.73; 95% CI, 0.57-0.94; P  .016). A
subgroup analysis of the 3% of women in the study who reported VTE before
randomization found they had a 44% hazard reduction (relative hazard,
0.56; 95% CI, 0.31-1.00; P  .048) with vitamin E supplementation.
Women without prior VTE had an 18% hazard reduction (relative hazard,
0.82; 95% CI, 0.68-0.99; P .040). In women with either the prothrombin
gene mutation or factor V Leiden, the hazard reduction was 49% with
vitamin E treatment (relative hazard, 0.51; 95% CI, 0.30-0.87; P  .014).
Comment: The Women’s Health Study itself, and many recent meta-
analysis, have not supported a recommendation for vitamin E supplementa-
tion to reduce overall cardiovascular events (JAMA 2005;295:56-65 and
Lancet 2003;361:2017-2023). The finding that vitamin E supplementation
may prevent VTE is, however, not at odds with these previous observations.
Arterial and venous events may not share similar mechanisms in all cases.
Given the size of this study and its prospective nature, it does appear vitamin
E may lower the risk of VTE, especially in woman with genetic risk factors.
Seasonal variation in surgical outcomes as measured by the American
College of Surgeons National Surgical Quality Improvement Program
(ACS-NSQIP)
Englesbe MJ, Pelletier SJ, Magee JC, et al. Ann Surg 2007;246:456-65.
Conclusion: There are seasonal variations in surgical outcomes with
respect to postoperative morbidity and mortality.
Summary: The complete experience of a surgical procedure is complex
and involves interactions between both systems and individuals. It is as-
sumed that increased surgeon experience can help produce favorable out-
comes. In July and August, there are relatively new trainees inmost academic
medical centers. At this time of the year, the trainees are less familiar with
their roles and responsibilities. It is postulated there may be more adverse
outcomes in surgical procedures performed early in the academic year vs
later. The authors propose that the National Surgical Quality Improvement
Program (NSQIP) is a database that is sufficiently large to allow a multi-
center, risk-adjustment analysis of surgical morbidity and mortality on a
month-to-month basis. In this study, the authors use 30-day morbidity and
mortality rates derived from NSQIP-participating hospitals and compared
two periods of care: an early group from July 1 to August 30 and a late group
from April 15 to June 15. The postoperative morbidity rate was 18% higher
in the early (n  9941) vs late (n  10, 310) groups (odds ratio, 1.18; 95%
confidence interval [CI], 1.07-1.29, P  .0005; c-index, 0.794). Mortality
was 41% higher in the early group compared with the late group (odds ratio,
1.41; 95% CI, 1.11-1.80; P  .005; c-index 0.938).
Comment: The study really cannot reliably implicate inexperience of
resident trainees as contributing to the so-called July effect. No hospitals
without training programs were included as controls. In addition, other
studies have suggested a “July effect” does not exist (Surgery 2001;130:
346-53 and J Gen Intern Med 2003;18:639-45). The authors also noted an
uptake in morbidity and mortality in December. At this point, resident
inexperience is not likely important. Also, many attending surgeons take a
vacation in July and August; therefore, slightly more urgent cases may be
performed in thosemonths than at other times of the year. It may be that less
attending supervision in peak vacationmonths or more urgent surgery in the
summer months and December are contributing more to seasonal variation in
surgical morbidity and mortality than the inexperience of resident physicians.
The female advantage in cardiovascular disease: Do vascular beds
contribute equally?
Kardys I, Vliegenthart R, Oudkerk M, et al. Am J Epidemiol 2007;166:
403-12.
Conclusion: There is a larger gender difference in atherosclerosis of
the coronary vessels than in other vascular beds, with women having less
severe disease than men. There are no gender differences in the aorta and
lower extremity vessels.
Summary: It is widely acknowledged that women have less incidence
of coronary heart disease than men. In this study, the authors sought to
characterize gender differences in cardiovascular disease according to vascu-
lar site. Degrees of coronary, carotid, peripheral, and aortic atherosclerosis
were compared in men and women aged 55 years from the population-
based Rotterdam Study. The study used data collected between 1997 and
